会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS
    • 有针对性的胃肠道传播和/或治疗药物
    • WO2014152338A1
    • 2014-09-25
    • PCT/US2014/027228
    • 2014-03-14
    • KABADI, MohanSCHENTAG, Jerome, J.
    • KABADI, MohanSCHENTAG, Jerome, J.
    • A61K9/48A61K47/38A61K47/30A61P3/00
    • A61K9/4808A61K9/4816A61K9/4866A61K9/4891A61K35/741A61K35/744A61K35/745A61K35/747
    • The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a mammal, most specifically the ileum and/or right colon of a human subject.
    • 本发明涉及用于口服递送益生菌或治疗剂用于各种适应症的靶向递送系统的开发,包括但不限于活化和预防艰难梭菌感染,抗生素相关性腹泻,肠易激综合征,克罗恩病, 肠道菌群替代,服用抗生素的患者的补充性菌群治疗,以及用于恢复代谢综合征症状治疗的患者中肠微生物群和肠细胞之间的平衡和信号转导,特别是糖尿病,胰岛素抵抗,肥胖,高脂血症和高血压。 本发明恢复了所述疾病特征的改变的益生菌生物失衡,以及定义了用于哺乳动物胃肠道中的益生菌生物体的特异性递送的平台技术开发,最特别地是一种哺乳动物的回肠和/或右结肠 人类科目。